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A B S T R A C T
MicroRNAs (miRNAs) are endogenous, single-stranded, short, noncoding ribonu-
cleic acids (RNAs), which can bind to their target messenger RNAs (mRNAs), lead-
ing to the inhibition of translation or degradation of the mRNA. Only recently have 
scientists discovered the important role that miRNAs play in gene regulation. To date, 
more than 700 miRNAs have been identified from the human genome. Malfunction-
ing miRNAs have been implicated in a number of diseases, due to their regulatory 
functions in transcription, signal transduction, cell cycle regulation, proliferation, cell 
growth and metabolism, cell apoptosis, and neurogenesis. Absence of miRNAs or 
their mutations, detected by genetic analysis, has been associated with a broad spec-
trum of disease processes, such as various cancers and autoimmune, cardiovascular, 
infectious, metabolic, neurodegenerative, skin, and psychiatric diseases. The large 
progress made in understanding miRNAs also points to their great potential as new 
biomarkers in the diagnosis and early detection of various diseases, as well as their 
promising role in future therapeutics.
I N T R O D U C T I O N
MicroRNAs (miRNAs) are endogenous, single-stranded, short (19-25 nucleotides 
in length), noncoding ribonucleic acids (RNAs), which can bind to complementary 
sequences in the three prime untranslated regions of their target messenger RNAs 
(mRNAs), leading to the inhibition of translation or degradation of the mRNA.1 
Only recently have scientists discovered the important role that miRNAs play in gene 
regulation, deemed as negative regulators of gene expression. To date, more than 
700 miRNAs have been identified from the human genome. Malfunctioning miRNAs 
have been implicated in a number of diseases, due to their regulatory functions in 
transcription, signal transduction, cell cycle regulation, proliferation, cell growth and 
metabolism, cell apoptosis, and neurogenesis. MicroRNAs, an abundant class of gene 
regulators, are highly expressed in regulatory T cells and a wide range of miRNAs are 
involved in the regulation of immunity and in the prevention of autoimmunity. Certain 
miRNAs serve in important negative feedback loops in the immune system, whereas 
others serve to amplify the response of the immune system by repressing inhibitors of 
the response. Absence of miRNAs or their mutations, detected by genetic analysis, has 
been associated with various cancers and diseases such as autoimmune, cardiovascular, 
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infectious, metabolic, neurodegenerative, skin, and psychiatric 
diseases (Table 1).1-12 This disease association may further 
lead to potential diagnostic (new biomarkers) and therapeutic 
applications of miRNA delivery. Different approaches have 
been proposed such as the modification of microRNAs and 
the use of viral delivery vectors. Commonly used methods for 
measuring miRNAs in the research setting, include Northern 
blot, polymerase chain reaction, and microarray. 
TABlE 1. Micro-RNAs in Various Diseases
DISEASE Micro-RNA FUNCTION / STATUS
Autoimmune Diseases
Asthma miR-21
miR-126
modulates interleukin (IL)-12
suppresses the asthmatic phenotype
Diabetes (autoimmune) miR-375 Negatively regulates glucose-stimulated insulin release in a calcium 
independent manner (the most abundant intra-islet miRNA)
61 glucose regulated 
miRNAs
most of these miRNAs are up-regulated / only few (miR-296, miR-184 &  
miR-160) are down-regulated
Inflammatory Bowel 
Disease (IBD)
miR-192, miR-375,  
miR-422b 
significantly decreased in the ulcerative colitis (UC) tissues 
miR-16, miR-21, miR-23a, 
miR-24, miR-29a,  
miR-126, miR-195, & let-7f
significantly increased in active UC tissues / miR-192 & miR-21 are the 
most highly expressed of the active UC-associated miRNAs in human 
colonic tissues
Multiple sclerosis (MS) hsa-miR-145
other 165 miRNAs 
the best single miRNA marker that allows discriminating MS from controls
165 miRNAs significantly up- or down-regulated
Psoriasis miR-203
miR-146a
miR-125b
keratinocyte-derived miRNA / up-regulation of miR-203 in psoriatic plaques
up-regulated, involved in the innate immune responses & the TNF-pathway 
Involved in TNF-pathway/also deregulated in psoriasis & atopic eczema
Rheumatoid arthritis miR-146 / miR-155
miR-223
Inhibition of TLR signalling / regulation of Th1 cells & mRNA for TNF-α
over-expressed in T cells (CD4+)
Scleroderma miR-29 down-regulates type I collagen mRNA, contributing to excessive collagen 
production
SLE miR-196a, miR-17-5p,  
miR-409-3p, miR-141,  
miR-383, miR-112, miR-184 
7 miRNAs down-regulated
miR-189, miR-61, miR-78, 
miR-21, miR-142-3p,  
miR-342, miR-299-3p,  
miR-198, miR-298
9 miRNAs up-regulated
Cardiovascular Diseases
Arrhythmia miR-1
miR-133
QRS & QT prolongation
Depression of Ikr and QT prolongation
Angiogenesis miR-92a
miR-130
miR-210
Inhibition of sprout formation and neovascularization
Promotion of angiogenesis caused by endothelial cell tube formation in vitro
Increase of endothelial cell migration and tubulogenesis
Cardiac fibrosis miR-21
miR-24
miR-29 / miR-133
Enhancement of ERK-MAP kinase pathway and fibroblast proliferation
Attenuates cardiac fibrosis after MI
Inhibition of fibrosis 
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TABlE 1. (continued) Micro-RNAs in Various Diseases
DISEASE Micro-RNA FUNCTION / STATUS
Cardiac hypertrophy miR-21 Promotion of cellular outgrowth
miR-23a / miR-195 Induction of hypertrophy
miR-133 Inhibition of cardiac hypertrophy
miR-208 Encoded by an intron of the a-MHC Modulation of activity of the thyroid 
hormone receptor
Cholesterol regulation miR-33 Inhibition of HDL formation
Myocardial infarction & 
cell death
miR-1
miR-1/206
Promotion of apoptosis, induced by H2O2 in H9c2 cells
Increase in mitochondrial depolarization in H9c2 cells
miR-21 Decrease of myocardial infarct size
miR-199a Stabilization of p53 and inhibit apoptosis
miR-499, miR-208a,  
miR-133a, miR-126 
Increase in circulation with myocardial injury (muscular miRNAs: miR-499, 
miR-208a & miR-133a; vascular miRNA: miR-126)
Neurodegenerative & Psychiatric Diseases
Alzheimer’s disease miR-107 / & other 18 
miRNAs
miR-1097 levels decreased significantly in Alzheimer’s disease / other 9 
upregulated & 9 downregulated miRNAs
Huntington’s disease 
(HD)
miR-9/miR-9* decreased in HD patient cortices
Schizophrenia miR-26b, miR-30b,  
miR-29b, miR-106b
disruption (global increase) in miRNA bio-genesis & expression in the cerebral 
cortex
Psychological stress miR-134 / miR-183 miRNA levels both increased in the amygdala following acute stress / chronic 
stress decreased miR-134 levels, whereas
miR-183 remained unchanged
ERK-MAP = extracellular signal-regulated kinase - microtubule-associated protein (kinase); HDL = high-density lipoprotein; IBD = inflammatory 
bowel disease (Crohn’s disease & ulcerative colitis); IL = interleukin; SLE = systemic lupus erythematosus; MHC = major histocompatibility 
complex; MI = myocardial infarction; TLRs = Toll-like receptors; TNF = tumor necrosis factor
C A N C E R
Increasing evidence is revealing that the expression of 
miRNAs is deregulated in cancer.4-6 The miRNA profiles 
of human solid and hematologic malignancies indicate their 
potential value as tumor markers in cancer patient therapy. 
Large-scale studies in human cancer have demonstrated that 
specific miRNA expressions are associated not only with spe-
cific tumor subtypes but also with clinical outcomes.4 Thus, 
the potential applications of miRNAs for cancer diagnosis, 
prognosis, and treatment are evident; however, miRNA-based 
cancer therapy currently remains an option for the future. A 
few examples of miRNA utility as diagnostic and prognostic 
markers are herein depicted. The microRNA let-7 family is 
associated with poor prognosis in lung and ovarian cancers, 
while it discriminates high-risk uveal melanomas; high expres-
sion of miR-15a and miR-16 are linked with poor prognosis 
in de novo aggressive chronic lymphocytic leukemia; miR-29c 
low expression correlates with short interval from diagnosis 
to therapy in chronic lymphocytic leukemia; poor prognosis 
is conferred by miR-21 high expression in colon and breast 
cancers; poor prognosis characterizes miR-155 high expression 
in lung cancer, diffuse large B-cell lymphoma, and aggres-
sive chronic lymphocytic leukemia; while good prognosis is 
indicated by miR-21 high expression in de novo diffuse large 
B-cell lymphoma.5 
A U T O I M M U N E  D I S E A S E S
An example of the miRNA role and involvement in the 
pathogenesis of autoimmune diseases relates to the expression 
of miR-29, which targets type I collagen mRNA, reported 
to be down-regulated in cultured dermal fibroblasts derived 
from scleroderma skin, contributing to excessive collagen 
production in this disease. Supplementation of the miRNA 
results in the decrease of collagen expression in scleroderma 
fibroblasts. In addition, serum miR-29a levels are significantly 
decreased in the very early stage of scleroderma. Similarly, 
in rheumatoid arthritis there is an increased expression in 
synovial fibroblasts of miR-146 and miR-155, shown to be 
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C A R D I O vA S C U l A R  D I S E A S E S
Recent studies indicate that miRNAs modulate a di-
verse spectrum of cardiac functions.2,3 Identifying circulating 
miRNAs can serve as novel biomarkers and diagnostic tools 
for diverse cardiovascular diseases (CVDs), including acute 
myocardial infarction, heart failure, coronary artery disease, 
arrhythmias, diabetes, stroke, hypertension, and pulmonary 
embolism.2,3,7-12 It appears that cardiac hypertrophy, heart 
failure, and myocardial infarction are each associated with 
distinct miRNA expression patterns. A few examples of specific 
miRNA cardiac pathologies are illustrated in Table 1. Two 
miRNAs that display cardiac and skeletal-muscle-specific 
expression during development are miR-1 and miR-133; these 
miRNAs have also been linked with arrhythmias. On the other 
hand, miR-199a is a master regulator of a hypoxia-triggered 
pathway and can be utilized for preconditioning cells against 
hypoxic damage. 3 
Recent studies have shown that some miRNAs are present 
in the circulation and the levels of circulating miRNAs have 
been reported for certain forms of CVD, such as in patients 
with myocardial infarction, hypothesizing that miRNAs in sys-
temic circulation may reflect tissue damage and, thus, they can 
be used as a biomarker of myocardial infarction.8-10 In patients 
with acute coronary syndromes, myocardial injury appears to 
be associated with cell type-specific expression or release of 
miRNAs. Thus, muscle cell-enriched miR-499 and miR-133a 
are released from the heart into the coronary circulation in 
such patients, while endothelial cell-enriched miR-126 is re-
duced during transcoronary passage.9 
Another miRNA type, miR-21, is among the most strongly 
upregulated miRNAs in response to a variety of forms of 
cardiac stress, upregulated in cardiac fibroblasts in the failing 
heart. In general, miRNAs are important regulators of cardiac 
fibrosis and are involved in structural heart disease. Important 
modulators of vascular disease and vessel remodeling may 
include miR-21, miR-155, miR126, miR-221 and miR-222. 
Studies have indicated that miR-33 controls cholesterol ho-
meostasis. In a recent study, in patients with heart failure, 4 
miRNAs were identified circulating in the plasma, miR-423-
5p, miR-320a, miR-22, and miR-92b, which may be used as 
markers for heart failure diagnosis.11 
In cases where reduction of a particular miRNA appears 
pathogenic, they can be remedied by increasing miRNA levels. 
In contrast, when miRNA overexpression plays a pathogenic 
role in a particular CVD, targeted treatment that leads to de-
creased levels of a specific miRNA would be beneficial (Table 
2). Thus, miRNA-mimics and anti-miRs are being developed, 
produced and employed in clinical studies.12 In order to reduce 
the effective concentration of an overexpressed endogenous 
miRNA and, subsequently, increase targeted gene expression, 
the delivery of either cholesterol- conjugated antisense miRNA 
inhibitors (antagomirs) or miRNA sponges (i.e., RNA contain-
ing 4–10 binding sites for the miRNA of interest) is required. 
induced by proinflammatory stimuli such as Toll-like recep-
tors (TLRs), interleukin (IL)-1 and, tumor necrosis factor 
(TNF)-α.1 Findings that over-expression of miR-146 and 
miR-155 suppresses T cell apoptosis indicate a possible role 
of these miRNAs in the pathogenesis of rheumatoid arthritis 
and provide potential novel therapeutic targets. In psoriasis, 
investigators have indicated that the affected skin has a specific 
miRNA expression profile; leukocyte-derived miRNAs and 
one keratinocyte-derived miRNA, miR-203, have been iden-
tified, and emerging data suggest that miRNA deregulation 
is involved in the pathogenesis of psoriasis. In patients with 
bronchial asthma, investigators have reported that selective 
blockade of miR-126 suppressed the asthmatic phenotype, 
resulting in diminished T helper-2 cell responses, inflamma-
tion, airways hyperresponsiveness, eosinophil recruitment, and 
mucus hypersecretion. These findings suggest that targeting 
miRNA in the airways may lead to anti-inflammatory treat-
ment of allergic asthma. Several miRNAs have been studied 
in diabetes mellitus; miR-375 has been identified as the most 
abundant intra-islet miRNA, deemed to be an important 
regulator of insulin release and glucose. 
I N F l A M M A T O R y  B O W E l  D I S E A S E
In inflammatory bowel disease, miR-192 and miR-21 are 
highly expressed in colonic tissues of patients with ulcerative 
colitis, while expression of miR-23b, miR-106, and miR-191 is 
increased in tissues from patients with active Crohn’s disease. 
Even peripheral blood miRNAs can be used to distinguish 
active Crohn’s disease and ulcerative colitis from healthy 
controls. 
N E U R O D E g E N E R A T I v E  A N D  P S y C h I A T R I C 
D I S O R D E R S
In neurodegenerative and psychiatric disorders, miRNAs 
also appear to play important roles.1 A number of reports have 
alluded to altered miRNA expression in neurological diseases 
(e.g. Parkinson’s disease, Alzheimer’s disease, Tourette’s syn-
drome, Huntington’s disease, Down syndrome, etc.), which may 
be a direct consequence of disease or may be derived from the 
loss of a specific cell population. It has been found that the 
best single miRNA marker, hsa-miR-145, allows for discern-
ing multiple sclerosis from controls with high sensitivity and 
specificity. Psychiatric and neurological disorders, comprising 
schizophrenia, depression and mental health disorders also 
appear to involve changes in miRNA expression. Studies have 
indicated that schizophrenia is associated with a global increase 
in miRNA biogenesis and expression in the cerebral cortex. 
Altered expression of miRNAs prior to the onset of or during 
the course of a disease raises the possibility that expressing or 
inhibiting specific miRNAs might favorably affect the disease 
process and provide an effective mode of therapy. 
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Preliminary studies have provided validating evidence of the 
efficacy of utilizing antagomirs and sponges to manipulate and 
silence miRNA function in vivo, thus therapeutically exploiting 
miRNAs. A few examples of effective miRNA therapeutics 
include the following: in vivo inhibition of miR-199b normal-
ized significantly attenuated cardiac functional impairment 
and fibrosis; miR-98 overexpression reduced angiotensin 
II-mediated fibrosis and amount of apoptotic myocytes; 
antagomir-21 decreased development of cardiac fibrosis and 
improved cardiac function; inhibition of miR-503 normalized 
post-ischemic flow; antagomir-320 reduced infarction size; 
antagomir-328 abrogated or stopped atrial fibrillation and im-
proved cardiac function post-myocardial infarction; a miR-33 
inhibitor increased plasma HDL levels. However, compared 
to classic drug delivery, severe challenges lie ahead since 
miRNAs have multiple molecular targets, which increases 
the probability that targeting of a miRNA may affect multiple 
cellular functions, some pathological and some beneficial. 
Such problems and caveats may pose significant hindrance to 
miRNA therapeutic approaches. 
C O N C l U S I O N
In conclusion, microRNAs, long considered as an unim-
portant element of ‘junk DNA’, have been recently demon-
strated to represent a group of endogenous noncoding RNAs 
pivotal in post-transcriptional regulation of gene expression. A 
plethora of research articles over the past several years, have 
shed light on the biogenesis of microRNA genes, their func-
tion, and their involvement in a broad spectrum of disease pro-
cesses. The large progress made in understanding microRNAs 
also points to their great potential in the diagnosis and early 
detection of various diseases, including different types of 
cancer and diseases such as autoimmune, cardiovascular, in-
fectious, metabolic, neurodegenerative, skin, and psychiatric 
diseases, as well as their promising role in future therapeutics. 
Continuing research will lead to enlightened new insights 
regarding the roles of these molecules in health and disease. 
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TABlE 2. Targets of MicroRNA Cardiovascular Thera-
peutics
Neointimal  
proliferation vascularization
• miR 21 ↓ miR 92a ↓
• miR 145 ↑ miR 503 ↓
• miR 221/222 ↓ miR 24 ↓
lipid metabolism Cardiac hypertrophy and fibrosis
• miR 122 ↓ • miR 133 ↑ • miR 21 ↓ • miR 24 ↑
• miR 33 ↓ • miR 199b ↓ • mir 29 ↑↓
• miR 98 ↑ • miR 208 ↓
Arrhythmogenesis Cell survival
• miR 328 ↓ • miR 15 ↓
• miR-1 ↓ • miR 320 ↓
↑ promote/increase; ↓ inhibit/block
